AR119268A1 - Métodos de purificación de anticuerpos y composiciones de estos - Google Patents
Métodos de purificación de anticuerpos y composiciones de estosInfo
- Publication number
- AR119268A1 AR119268A1 ARP200101639A ARP200101639A AR119268A1 AR 119268 A1 AR119268 A1 AR 119268A1 AR P200101639 A ARP200101639 A AR P200101639A AR P200101639 A ARP200101639 A AR P200101639A AR 119268 A1 AR119268 A1 AR 119268A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- seq
- set forth
- protein
- matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un método para obtener una composición que comprende un anticuerpo anti-a4b7 a partir de una solución líquida que comprende el anticuerpo anti-a4b7 y una o más impurezas, dicho método comprende poner en contacto una matriz que comprende proteína A con la solución líquida que comprende el anticuerpo anti-a4b7 y una o más impurezas, de manera que el anticuerpo anti-a4b7 se una a la proteína A; lavar la matriz que comprende la proteína A con una solución de lavado; y eluir el anticuerpo anti-a4b7 de la matriz que comprende la proteína A al poner en contacto la matriz con una solución de elución con un pH de 3,2 a 4, de modo que se obtenga una composición que comprende el anticuerpo anti-a4b7, donde el anticuerpo anti-a4b7 es un anticuerpo humanizado, es un anticuerpo IgG1, comprende una región variable de cadena pesada que comprende un dominio de CDR3 tal como se establece en la SEQ ID Nº 4, un dominio de CDR2 tal como se establece en la SEQ ID Nº 3 y un dominio de CDR1 tal como se establece en la SEQ ID Nº 2 y comprende una región variable de cadena ligera que comprende un dominio de CDR3 tal como se establece en la SEQ ID Nº 8, un dominio de CDR2 tal como se establece en la SEQ ID Nº 7 y un dominio de CDR1 tal como se establece en la SEQ ID Nº 6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859580P | 2019-06-10 | 2019-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119268A1 true AR119268A1 (es) | 2021-12-09 |
Family
ID=73782230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101639A AR119268A1 (es) | 2019-06-10 | 2020-06-10 | Métodos de purificación de anticuerpos y composiciones de estos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220259291A1 (es) |
| EP (1) | EP3980119A4 (es) |
| JP (1) | JP2022536659A (es) |
| CN (1) | CN114025843A (es) |
| AR (1) | AR119268A1 (es) |
| AU (1) | AU2020290999A1 (es) |
| BR (1) | BR112021024848A2 (es) |
| CA (1) | CA3143169A1 (es) |
| IL (1) | IL288830A (es) |
| MA (1) | MA56132A (es) |
| MX (1) | MX2021015302A (es) |
| PL (1) | PL439807A1 (es) |
| TW (1) | TW202112800A (es) |
| WO (1) | WO2020252072A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019198099A1 (en) * | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2023012828A1 (en) * | 2021-08-05 | 2023-02-09 | Dr. Reddy's Laboratories Limited | Method to purify an antibody composition using cation exchange chromatography |
| EP4396195A1 (en) * | 2021-09-03 | 2024-07-10 | Dr. Reddy's Laboratories Limited | Method to obtain a purified antibody composition |
| WO2023180523A1 (en) * | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2453558C2 (ru) * | 2004-09-03 | 2012-06-20 | Дженентек, Инк. | Гуманизированные антагонистические антитела против бета7 и их применение |
| TWI723339B (zh) * | 2011-05-02 | 2021-04-01 | 美商千禧製藥公司 | 抗-α4β7抗體之調配物 |
| PL3116891T3 (pl) * | 2014-03-10 | 2020-07-27 | Richter Gedeon Nyrt. | Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania |
| WO2018104893A1 (en) * | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
-
2020
- 2020-06-10 CN CN202080042562.6A patent/CN114025843A/zh active Pending
- 2020-06-10 BR BR112021024848A patent/BR112021024848A2/pt unknown
- 2020-06-10 WO PCT/US2020/037069 patent/WO2020252072A1/en unknown
- 2020-06-10 PL PL439807A patent/PL439807A1/pl unknown
- 2020-06-10 AR ARP200101639A patent/AR119268A1/es unknown
- 2020-06-10 JP JP2021573301A patent/JP2022536659A/ja active Pending
- 2020-06-10 EP EP20823674.5A patent/EP3980119A4/en active Pending
- 2020-06-10 US US17/596,422 patent/US20220259291A1/en active Pending
- 2020-06-10 MX MX2021015302A patent/MX2021015302A/es unknown
- 2020-06-10 CA CA3143169A patent/CA3143169A1/en active Pending
- 2020-06-10 MA MA056132A patent/MA56132A/fr unknown
- 2020-06-10 AU AU2020290999A patent/AU2020290999A1/en active Pending
- 2020-06-10 TW TW109119565A patent/TW202112800A/zh unknown
-
2021
- 2021-12-09 IL IL288830A patent/IL288830A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020252072A1 (en) | 2020-12-17 |
| MA56132A (fr) | 2022-04-13 |
| JP2022536659A (ja) | 2022-08-18 |
| BR112021024848A2 (pt) | 2022-01-18 |
| US20220259291A1 (en) | 2022-08-18 |
| IL288830A (en) | 2022-02-01 |
| AU2020290999A1 (en) | 2022-02-03 |
| TW202112800A (zh) | 2021-04-01 |
| CA3143169A1 (en) | 2020-12-17 |
| CN114025843A (zh) | 2022-02-08 |
| EP3980119A4 (en) | 2023-06-07 |
| MX2021015302A (es) | 2022-01-18 |
| PL439807A1 (pl) | 2022-12-05 |
| EP3980119A1 (en) | 2022-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119268A1 (es) | Métodos de purificación de anticuerpos y composiciones de estos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20121646A1 (es) | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| PE20110801A1 (es) | Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| RS54113B1 (en) | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN | |
| NZ581418A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
| CO6251371A2 (es) | Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| PE20070183A1 (es) | Anticuerpos monoclonales anti-trkb | |
| PE20190212A1 (es) | Anticuerpos anti_ige | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| PE20040947A1 (es) | MOLECULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| CO6331370A2 (es) | Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| RS54393B1 (en) | HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR |